Authors:

Gadducci A. Fanucchi A. Cosio S. Genazzani AR.

Institution:

A. Gadducci, Department Gynecology and Obstetrics, University of Pisa, Via Roma 67, 56127 Pisa; Italy.

Title:

Hormone replacement therapy and gynecological cancer (1997-2102).

Source:

Anticancer Research. Vol 17(5 B) (pp793-3798), 1997.

Abstract:

The aim of this paper is to report the risk of development of gynecological cancer in women receiving hormone replacement therapy and to review the current knowledge on the administration of hormone replacement therapy following treatment of gynecological cancer. Estrogens alone may act as promoting factors for endometrial carcinogenesis. However, the addition of progenestins reduces the risk of endometrial cancer to that of nonusers. Hormone replacement therapy could be given to selected patients following treatment for endometrial cancer. However, we think that this therapy should be reserved only for patients enrolled in controlled clinical trials. Ovarian cancer does not seem to be sensitive to estrogens, even if current literature does not allow firm conclusions to be drawn. Hormone replacement therapy should be offered to patients previously treated for ovarian cancer and cervical cancer.




Please click on the required question.

Women's Health

Women's Health Forum

Thank you for choosing to visit us.

This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.

I do hope that you find the answers to your questions in the patient information and medical advice provided. If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.

HRT Uterine Cancer

Women's Health